Selective inactivation of muscarinic receptor subtypes

https://doi.org/10.1016/0020-711X(94)90178-3Get rights and content

Abstract

Muscarinic receptors exist in multiple subtypes, denoted as M1, M2 M3 and M4, encoded by four distinct but related genes. A fifth gene product, m5, has also been predicted although this sequence awaits a pharmacological equivalent. Many tissues express more than one muscarinic receptor subtype, which may couple to different intracellular effectors and thus have different physiological roles. One way to characterize the role of each receptor is to selectively inactivate one receptor population, thus pharmacologically ‘isolating’ the muscarinic receptor subtype of interest. Selective receptor inactivation can be achieved using either a selective, irreversible antagonist, or protection using a selective, reversible antagonist against a non-selective irreversible antagonist. Therefore, combination of these two approaches may provide optimal selective inactivation. Several muscarinic alkylating agents have been identified, including phenoxybenzamine, EEDQ (N-Ethoxycarbonyl-1-ethoxy-1,2-dihydroquinoline) and propylbenzilylcholine mustard. These irreversible antagonists do not, in general, discriminate between muscarinic receptor subtypes and are frequently used to estimate the affinity and relative efficacy of muscarinic agonists. Consequently, use of these irreversible antagonists provides estimations of the ‘receptor reserve’ associated with a response mediated by muscarinic receptor activation. In contrast, 4-DAMP mustard (4-diphenylacetoxy-N-(2-chloroethyl)piperidine) selectively inactivates M3 receptors, but will not discriminate between M1 M 2 or M4 receptors. In the absence of highly selective alkylating agents, receptor protection by reversible antagonists may be used. Thus, reversible antagonists, such as pirenzepine, methoctramine or para-fluorohexahydrosiladifenidol, at appropriate fractional receptor occupancies, may protect M1 M2 or M3 receptors against alkylation by phenoxybenzamine. Selective alkylation of M3 receptors by 4-DAMP mustard is enhanced with concurrent M2 protection. This approach has been applied to defining the role of these muscarinic receptor subtypes in the control of ileal smooth muscle tone. These data suggest that, in ileum, M2 receptors may act to inhibit β-adrenoceptor activation, thereby offsetting relaxation, while M3 receptors directly mediate contraction.

References (64)

  • G. Lambrecht et al.

    New functionally selective muscarinic agonists

    Life Sci.

    (1993)
  • S.W. McLeskey et al.

    Identification of muscarinic receptor subtypes present in cerebellar granule cells: prevention of [3H]propylbenzilyl choline mustard binding with specific antagonists

    Neuropharmacol

    (1990)
  • G. Milligan

    Mechanisms of multifunctional signalling by G protein-linked receptors

    Trends Pharmac. Sci.

    (1993)
  • L.T. Potter et al.

    ml-Toxin

    Life Sci.

    (1993)
  • M. Sokolovsky

    Photoaffinity labeling of muscarinic receptors

    Pharmac. Ther.

    (1987)
  • T.A. Spalding et al.

    Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors

    J. biol. Chem.

    (1994)
  • I. Takayanagi et al.

    Propylbenziylcholine mustard-sensitive and resisitant muscarinic receptors in cardiac muscle

    Gen. Pharmac.

    (1991)
  • A.B. Tobin et al.

    Phosphorylation of a phosphoinositidase C-linked muscarinic receptor by a novel kinase distinct from beta-adrenergic receptor kinase

    FEBS Letts.

    (1993)
  • M. Waelbroeck et al.

    Inactivation of brain cortex muscarinic receptors by 4-diphenylacetoxy-1-(2-chloro-ethyl) piperidine mustard

    Biochem. Pharmac.

    (1992)
  • J. Wess

    Mutational analysis of muscarinic acetylcholine receptors: structural basis of ligand/receptor/G protein interactions

    Life Sci.

    (1993)
  • B.T. Zhu

    The competitive and noncompetitive antagonism of receptor mediated drug actions in the presence of spare receptors

    J. Pharmac. Meths.

    (1993)
  • R.B. Barlow et al.

    A comparison of affinity constants for muscarine-sensitive acetylcholine receptors in guinea-pig atrial pace-maker cells at 29°C and in ileum at 29°C and 37°C

    Br. J. Pharmac.

    (1976)
  • R.B. Barlow et al.

    Some differential effects of 4-diphenylacetoxy-N-(2-chloroethyl)-piperidine hydrochloride on guinea-pig atria and ileum

    J. Pharm. Pharmac.

    (1990)
  • J.H. Brown et al.

    Differences in muscarinic receptor reserve for inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis in chick heart cells

    Molec. Pharmac.

    (1986)
  • A.S.V. Burgen

    History and basic properties of the muscarinic cholinergic receptors

  • A.S.V. Burgen et al.

    The binding of [3H]propylbenzilylcholine mustard by longitudinal strips from guinea-pig small intestine

    Br. J. Pharmac.

    (1974)
  • D. Colquhoun

    Affinity, efficacy and receptor classification: is the classical theory still useful?

  • H.H. Dale

    The action of certain esters and ethers of choline and their relation to muscarine

    J. Pharmac. exp. Ther.

    (1914)
  • F. Dorje et al.

    Antagonist binding profiles of five cloned human muscarinic receptor subtypes

    J. Pharmac. exp. Ther.

    (1991)
  • R.M. Eglen et al.

    Muscarinic activity of McN-A-343 and its value in muscarinic receptor classification

    Br. J. Pharmac.

    (1987)
  • R.M. Eglen et al.

    Selective inactivation of muscarinie M2 and M3 receptors in guinea-pig ileum and atria in vitro

    Br. J. Pharmac.

    (1993)
  • R.M. Eglen et al.

    The interaction of zamifenacin at muscarinic receptor subtypes in vitro

  • Cited by (38)

    • Anticholinergic agents

      1998, Pulmonary Pharmacology and Therapeutics
    View all citing articles on Scopus
    View full text